Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Oct 22, 2014
Sangamo BioSciences Reports Third Quarter 2014 Financial Results

Oct 16, 2014
Sangamo BioSciences ZFP Therapeutic Program in HIV/AIDS Featured at Three Major Scientific Conferences in October 2014


Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
11.91
Change:
+ 0.04
Day High:
12.06
Day Low:
11.69
Volume:
535,700
4:00 PM ET on Oct 30, 2014

Shareholder Tools